Skip to Content

Dialysis Patients Have Weaker Response to COVID Vaccine: Study

FRIDAY, May 14, 2021 -- A single dose of a COVID-19 vaccine isn't enough to develop adequate antibodies in kidney dialysis patients, Canadian researchers report.

"We advise that the second dose of the [Pfizer] vaccine be administered to patients receiving hemodialysis at the recommended 3-week time interval and that rigorous SARS-CoV-2 infection prevention and control measures be continued in hemodialysis units until vaccine efficacy is known," said researcher Dr. Rita Suri, a kidney specialist at the Research Institute of McGill University Health Center in Montreal.

Dialysis patients are especially vulnerable to COVID as they must visit a treatment center three times a week. Among these patients, between 20% and 30% of cases are fatal — 10 times higher than in the general population.

The study included 154 dialysis patients, 40 healthy volunteers and plasma from 16 dialysis patients who survived COVID.

After one dose of the Pfizer vaccine, antibodies could not be detected in 57% of dialysis patients, researchers found. Of those, four developed COVID after vaccination.

"Patients receiving hemodialysis who did not respond at 4 weeks remained non-responders at eight weeks, which is an argument against the possibility of a delayed response in these individuals," the authors wrote.

Older patients and those on immunosuppressant drugs had even lower rates of producing antibodies, according to the study. In addition, younger patients who were not on the drugs had a significantly lower rate of antibody production than the healthy control group, researchers wrote.

How well dialysis patients respond to the second dose of vaccine is under study.

The findings were published May 12 in the Canadian Medical Association Journal.

Sources

  • Canadian Medical Association Journal, news release, May 12, 2021

© 2021 HealthDay. All rights reserved.

Read this next

Health Highlights: June 18, 2021

EU Opens Doors to American Travelers The European Union announced Friday that it will no longer ban U.S. tourists from traveling to Europe. The move will undoubtedly be welcome...

U.S. to Spend $3.2 Billion to Help Develop Antiviral Pills for COVID

FRIDAY, June 18, 2021 -- After spending billions to speed the creation of COVID-19 vaccines, the United States said Thursday that it will now devote $3.2 billion to the...

Hospitals: One Reason COVID Is More Lethal for Black Americans

FRIDAY, June 18, 2021 -- Black COVID-19 patients in the United States are more likely to die than white patients, but there would be 10% fewer deaths among Black patients if they...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.